HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[RADICAL SEGMENTECTOMY AND WEDGE RESECTION FOR GOOD-RISK PATIENTS WITH PERIPHERAL CT1AN0M0 LUNG CANCERRADICAL SEGMENTECTOMY AND WEDGE RESECTION FOR GOOD-RISK PATIENTS WITH PERIPHERAL CT1AN0M0 LUNG CANCER].

Abstract
Lobectomy has been and remains the standard surgical treatment for peripheral cT1aN0M0 lung cancer because of the conclusion of the randomized controlled trial performed by the Lung Cancer Study Group in 1995, and limited resection (segmentectomy and wedge resection) is still not the standard treatment for patients who are candidates for lobectomy; limited resection compared with lobectomy was statistically associated with a significantly greater incidence of local recurrence, although no statistically significant difference was identified in overall survival. In 2002, a Japanese prospective single-arm study of peripheral cT1aN0M0 lung cancer revealed no significantly different outcomes between segmentectomy and lobectomy with aggressive lymph node examination using frozen sections and wide surgical margins; the 5-year survival rate was 81.8% and local recurrence rate was 1.8%. Recently, two clinical trials conducted by the Japan Clinical Oncology Group (JCOG) have completed patient enrollment: JCOG0802, a phase III randomized trial of lobectomy versus segmentectomy for small peripheral non-small cell lung cancer; and JCOG0804, a nonrandomized confirmatory study of limited surgical resection for peripheral early lung cancer as defined based on thoracic thin-section computed tomography. The results will be published in the near future, and the standard treatment for peripheral cT1aN0M0 lung cancer may change.
AuthorsMasahiro Yoshimura
JournalNihon Geka Gakkai zasshi (Nihon Geka Gakkai Zasshi) Vol. 117 Issue 4 Pg. 278-82 (Jul 2016) ISSN: 0301-4894 [Print] Japan
PMID30160462 (Publication Type: Journal Article)
Topics
  • Aged
  • Female
  • Humans
  • Lung Neoplasms (surgery)
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Pneumonectomy
  • Risk Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: